Valeritas gets US nod to use V-Go device to deliver Novo Nordisk's insulin
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for the use of the V-Go disposable insulin delivery device, developed by Valeritas, with Novo Nordisk's NovoLog, a fast-acting form of insulin. V-Go permits continuous subcutaneous delivery of insulin in preset basal rates, along with on-demand bolus dosing for adult patients. Patients with type 2 diabetes apply a new V-Go to the skin daily for 24 hours. In December, the FDA cleared use of the V-Go with Eli Lilly's Humalog fast-acting insulin. NovoLog and Humalog are the two most widely prescribed fast-acting insulins in the US, Bridgewater, New Jersey-based Valeritas says.